DK577783D0 - Vektor for udtrykkelse af et dna-segment i gaer - Google Patents

Vektor for udtrykkelse af et dna-segment i gaer

Info

Publication number
DK577783D0
DK577783D0 DK5777/83A DK577783A DK577783D0 DK 577783 D0 DK577783 D0 DK 577783D0 DK 5777/83 A DK5777/83 A DK 5777/83A DK 577783 A DK577783 A DK 577783A DK 577783 D0 DK577783 D0 DK 577783D0
Authority
DK
Denmark
Prior art keywords
gaer
vector
expression
dna segment
dna
Prior art date
Application number
DK5777/83A
Other languages
English (en)
Other versions
DK173604B1 (da
DK577783A (da
Inventor
Rae Lyn Burke
Patricia Tekamp-Olson
Steven Rosenberg
Pablo D T Valenzuela
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23860419&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK577783(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of DK577783D0 publication Critical patent/DK577783D0/da
Publication of DK577783A publication Critical patent/DK577783A/da
Priority to DK199301074A priority Critical patent/DK173763B1/da
Application granted granted Critical
Publication of DK173604B1 publication Critical patent/DK173604B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Toys (AREA)
DK198305777A 1983-02-22 1983-12-15 Vektor for udtrykkelse i gær, bestående af et fremmed DNA-kodningssegment og en fremgangsmåde til udtrykkelse af DNA-kodningssegmentet i gær ved hjælp af en sådan vektor DK173604B1 (da)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK199301074A DK173763B1 (da) 1983-02-22 1993-09-23 Vektor for udtrykkelse i gær med en PyK promotor og en fremgangsmåde til syntese af hepatitis B virus overfladeantigen ved hjælp af en sådan vektor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46858983A 1983-02-22 1983-02-22
US46858983 1983-02-22

Publications (3)

Publication Number Publication Date
DK577783D0 true DK577783D0 (da) 1983-12-15
DK577783A DK577783A (da) 1984-08-23
DK173604B1 DK173604B1 (da) 2001-04-23

Family

ID=23860419

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198305777A DK173604B1 (da) 1983-02-22 1983-12-15 Vektor for udtrykkelse i gær, bestående af et fremmed DNA-kodningssegment og en fremgangsmåde til udtrykkelse af DNA-kodningssegmentet i gær ved hjælp af en sådan vektor

Country Status (7)

Country Link
EP (4) EP0329203B1 (da)
JP (2) JPS59210888A (da)
AT (3) ATE93894T1 (da)
CA (2) CA1341116C (da)
DE (3) DE3486431T3 (da)
DK (1) DK173604B1 (da)
SG (1) SG48422A1 (da)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
JPS5931799A (ja) * 1982-08-16 1984-02-20 Science & Tech Agency Ｂ型肝炎ウイルス遺伝子を組込んだ組換えプラスミド
JPS5936699A (ja) * 1982-08-20 1984-02-28 Chemo Sero Therapeut Res Inst シヤトルベクタ−
US5422267A (en) * 1984-05-22 1995-06-06 Robert R. Yocum Industrial yeast comprising an integrated glucoamylase gene
EP0173997A1 (en) * 1984-09-06 1986-03-12 Chiron Corporation Feline leukemia virus protein vaccines and their preparation
DE3587307T2 (de) * 1984-12-06 1993-09-02 Fina Research Transformierte hefen die lysozym produzieren, fuer diese transformation zu verwendende plasmide und deren verwendung.
DE3677851D1 (de) * 1985-08-05 1991-04-11 Merck & Co Inc Verfahren zur steigerung der produktion von rekombinantem protein in hefearten der gattung saccharomyces.
ES2028779T3 (es) * 1985-10-03 1992-07-16 Green Cross Corporation Promotor de levadura y procedimiento para preparar proteina heterologa.
JPH0655155B2 (ja) * 1985-10-03 1994-07-27 株式会社ミドリ十字 蛋白質の製造方法
DK162900C (da) * 1985-10-24 1992-05-11 Danisco Fremgangsmaade til ekspression af gener i gaer samt dna-fragment, rekombineret dna-segment og plasmider, hvor disse indgaar til brug ved udoevelse af fremgangsmaaden
US4895800A (en) * 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
JPS62236496A (ja) * 1986-04-07 1987-10-16 Green Cross Corp:The ＨＢｓＡｇの製造方法
US4839283A (en) * 1986-12-30 1989-06-13 Zymogenetics, Inc. Method of expressing alpha-1-antitrypsin in yeast
ES2167304T3 (es) * 1987-06-22 2002-05-16 Medeva Holdings Bv Peptido que contiene el antigeno de superficie de la hepatitis b.
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
AU644619B2 (en) 1989-12-21 1993-12-16 Advanced Technologies (Cambridge) Limited Modification of plant metabolism
NZ236434A (en) * 1990-01-29 1992-08-26 Ciba Geigy Ag Dna molecules comprising the a niger pyruvate kinase transcription promoter, vectors containing it and their use in transforming host cells
US6194140B1 (en) * 1990-04-04 2001-02-27 Chiron Corporation HCV NS3 protein fragments having helicase activity and improved solubility
WO1992009698A1 (en) 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
ATE249838T1 (de) 1993-05-12 2003-10-15 Chiron Corp Konserviertes motiv der hepatitis c virus e2/ns1 region
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
JPH08173170A (ja) * 1994-05-25 1996-07-09 Kirin Brewery Co Ltd キャンディダ・ユティリス酵母の形質転換系、およびそれによる異種遺伝子の発現
US5728676A (en) * 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
AU725340B2 (en) 1995-12-22 2000-10-12 Gist-Brocades B.V. Improved methods for transforming Phaffia strains, transformed Phaffia strains so obtained and recombinant DNA in said methods
EP1900818A3 (en) 1997-11-06 2008-06-11 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigens
CA2317815A1 (en) 1998-01-14 1999-07-22 Chiron S.P.A. Neisseria meningitidis antigens
US6087128A (en) 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
EP2261343A3 (en) 1998-05-01 2012-01-18 Novartis Vaccines and Diagnostics, Inc. Neisseria meningitidis antigens and compositions
DK1228217T3 (da) 1999-04-30 2013-02-25 Novartis Vaccines & Diagnostic Konserverede neisseria-antigener
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
ES2543736T3 (es) 1999-10-29 2015-08-21 Glaxosmithkline Biologicals Sa Péptidos antigénicos de Neisseria
US6709863B2 (en) 1999-12-08 2004-03-23 Iowa State University Research Foundation Nucleic acid molecules encoding multiple start codons and histidine tags
DK2289545T3 (da) 2000-01-17 2016-09-05 Glaxosmithkline Biologicals Sa Suppleret OMV-vaccine mod meningococcus
MXPA03003690A (es) 2000-10-27 2004-05-05 Chiron Spa Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
US8008459B2 (en) 2001-01-25 2011-08-30 Evolva Sa Concatemers of differentially expressed multiple genes
ATE501251T1 (de) 2001-01-25 2011-03-15 Evolva Ltd Zellbibliothek
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
DE60228758D1 (de) 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
AU2003243316A1 (en) 2002-05-24 2003-12-12 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
DE60332477D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
PL1704234T3 (pl) 2003-11-21 2012-06-29 Nps Pharma Inc Wytwarzanie glukagonopodobnego peptydu 2 i analogów
DE10356218A1 (de) * 2003-12-03 2005-06-30 Bayer Cropscience Ag Verfahren zum Identifizieren von fungizid wirksamen Verbindungen basierend auf Pyruvatkinasen aus Pilzen
KR20070007086A (ko) 2004-02-02 2007-01-12 암브룩스, 인코포레이티드 변형된 인간의 4 개의 나선형 다발 폴리펩티드 및 이의용도
BRPI0512235A (pt) 2004-06-18 2008-02-19 Ambrx Inc polipeptìdeos ligadores de antìgenos e seus usos
AU2005319518B2 (en) 2004-12-22 2010-09-09 Ambrx, Inc. Compositions of aminoacyl-tRNA synthetase and uses thereof
CA2594557C (en) 2004-12-22 2016-04-26 Ambrx, Inc. Modified human growth hormone
CA3005835C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
CN102703446B (zh) 2005-08-18 2014-05-28 Ambrx公司 tRNA组合物和其用途
CA2621023C (en) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Multiple vaccination including serogroup c meningococcus
WO2007059312A2 (en) 2005-11-16 2007-05-24 Ambrx, Inc. Methods and compositions comprising non-natural amino acids
CA2631491C (en) 2005-12-14 2015-02-24 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
US9133495B2 (en) 2006-09-08 2015-09-15 Ambrx, Inc. Hybrid suppressor tRNA for vertebrate cells
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
WO2008139591A1 (ja) * 2007-05-11 2008-11-20 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 組換えアプロチニンの生産方法
ES2632504T3 (es) 2007-11-20 2017-09-13 Ambrx, Inc. Polipéptidos de insulina modificados y sus usos
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
NZ600382A (en) 2008-07-23 2013-11-29 Ambrx Inc Modified bovine G-CSF polypeptides and their uses
ES2660000T3 (es) 2008-09-26 2018-03-20 Ambrx, Inc. Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
WO2010036964A2 (en) 2008-09-26 2010-04-01 Ambrx Inc. Modified animal erythropoietin polypeptides and their uses
CN102753573A (zh) 2009-12-21 2012-10-24 Ambrx公司 经过修饰的牛促生长素多肽和其用途
EP2805965A1 (en) 2009-12-21 2014-11-26 Ambrx, Inc. Modified porcine somatotropin polypeptides and their uses
EP2571991A1 (en) 2010-05-20 2013-03-27 Evolva SA Method of producing isoprenoid compounds in yeast
PL2605789T3 (pl) 2010-08-17 2019-11-29 Ambrx Inc Zmodyfikowane polipeptydy relaksyny i ich zastosowania
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
CA2965502A1 (en) 2014-10-24 2016-04-28 Bristol-Myers Squibb Company Modified fgf-21 polypeptides and uses thereof
MX2019008449A (es) 2017-02-08 2019-09-09 Bristol Myers Squibb Co Polipetidos de relaxina modificada que comprenden un mejorador farmacocinetico y sus usos.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
GR76274B (da) * 1981-08-04 1984-08-04 Univ California
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
US4446235A (en) * 1982-03-22 1984-05-01 Genentech, Inc. Method for cloning human growth hormone varient genes
JPS59501572A (ja) * 1982-05-19 1984-09-06 ユニリーバー　ナームローゼ　ベンノートシヤープ クルイベロミセス属酵母およびその製造法
AU577259B2 (en) * 1982-08-13 1988-09-22 Zymogenetics Inc. Glycolytic promters for regulated protein expression protease inhibitor
JPH0716432B2 (ja) * 1982-10-20 1995-03-01 サントリー株式会社 酵母の高発現ベクタープラスミドを用いたペプチドの生産方法

Also Published As

Publication number Publication date
DK173604B1 (da) 2001-04-23
JPH05268984A (ja) 1993-10-19
JPS59210888A (ja) 1984-11-29
DE3486206T2 (de) 1994-02-03
EP0120551A3 (en) 1986-05-14
DK577783A (da) 1984-08-23
CA1341302C (en) 2001-10-09
DE3486206D1 (de) 1993-10-07
DE3486431D1 (de) 1996-07-11
JPH0515431B2 (da) 1993-03-01
EP0329203A1 (en) 1989-08-23
EP0329203B1 (en) 1993-09-01
CA1341116C (en) 2000-10-17
EP0460716B2 (en) 1999-12-15
ATE93894T1 (de) 1993-09-15
DE3482844D1 (de) 1990-09-06
EP0460716A1 (en) 1991-12-11
DE3486431T2 (de) 1996-10-10
EP0120551A2 (en) 1984-10-03
DE3486431T3 (de) 2000-05-04
EP0460716B1 (en) 1996-06-05
ATE55151T1 (de) 1990-08-15
ATE138975T1 (de) 1996-06-15
JPH0724594B2 (ja) 1995-03-22
SG48422A1 (en) 1998-04-17
EP0120551B1 (en) 1990-08-01
EP0732403A1 (en) 1996-09-18

Similar Documents

Publication Publication Date Title
DK577783D0 (da) Vektor for udtrykkelse af et dna-segment i gaer
ES8605039A1 (es) Procedimiento para preparar una vacuna que comprende un derivado truncado, libre de una membrana de un tipo fijado a una membrana que tiene determinantes antigenicos expuestos.
DE3588252D1 (de) Rekombinante Proteine von mit Lymphadenopathiesyndrom und/oder erworbenem Immunschwächesyndrom assoziierten Viren
PT83819A (en) Yeast production of hepatitis b surface antigen
EP0260148A3 (en) Improved recombinant expression method, vector and transformed cells
ES8602119A1 (es) Metodo para preparar inmunoglobulinas en celulas hospedantes recombinantes
ES8105388A1 (es) Un metodo para mantener, replicar y expresar por lo menos una porcion del genoma de un virus n.p.
DK5491A (da) Anvendelser af virale enzymer
EP0247730A3 (en) Antibodies, their preparation and use and products containing them
NO854460L (no) Syntetisk hepatitis-b-vaksine inbefattende baade t-celle og b-celledeterminanter.
ES8706208A1 (es) Un metodo para preparar proteinas que son inmunologicamente reactivas con anticuerpos para virus asociados con linfadenopatia
ES8600939A1 (es) Un procedimiento para preparar una vacuna para el virus de la hepatitis b
ES8608581A1 (es) Un metodo para la construccion de un gen sintetico para pro-teina objetivo viral
EP0228036A3 (en) Method for producing selected polypeptides in virally infected insect cells and polypeptides isolated therefrom
DK0396436T3 (da) Gærstammer til fremstilling af modne heterologe proteiner, især hirudin
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
DK107493A (da) Vektor for udtrykkelse i gaer, bestaaende af et fremmed dna-segment og en fremgangsmaade til syntese af fremmede proteiner ved hjaelp af en saadan vektor
ATE49401T1 (de) Verfahren zur herstellung von alkylarylethern.
DK204586A (da) Hybridceller, der producerer et karakteristisk antigen for hepatitis b-virus, opnaaet ud fra hepatocytter og celler, der er tilvejebragt fra aber, fremgangsmaade til opnaaelse af hybridcellerne og anvendelse af disse til produktion af antigenet
ATE59679T1 (de) Herstellung von herpes-simplex-virusproteinen.
DK0635061T3 (da) Fremgangsmåde til begrænsning af genetisk manipulerede organismers overlevelse i deres miljø
SU1380209A1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК PUR 291-HAV 22, КОДИРУЮЩАЯ СИНТЕЗ ГИБРИДНОГО ПОЛИПЕПТИДА АНТИГЕННЫХ ДЕТЕРМИНАНТ ВИРУСА ГЕПАТИТА А С β -ГАЛАКТОЗИДАЗОЙ
McGee Factors affecting the cellular specificity of vesicular stomatitis virus mediated cell fusion
ES8801948A1 (es) Un procedimiento para la preparacion de un transformante que comporta un vector de expresion que comprende un gen que codifica una proteina envolvente de un virus de sida
AU8277582A (en) Method for the preparation of a dna-hybride, containing the complementary genome of the hepatitis a virus, the dna- hybride itself, the plasmic vector contain it, the specific proteins of the virus coded by the dna-hybride and vaccines containing them

Legal Events

Date Code Title Description
B1 Patent granted (law 1993)
PUP Patent expired